Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects
Open Access
- 3 November 2016
- journal article
- research article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 4 (6) , e00271
Abstract
Buprenorphine is mainly metabolized by the cytochrome P450 (CYP) 3A4 enzyme. The aim of this study was to evaluate the role of first-pass metabolism in the interaction of rifampicin and analgesic doses of buprenorphine. A four-session paired cross-over study design was used. Twelve subjects ingested either 600 mg oral rifampicin or placebo once daily in a randomized order for 7 days. In the first part of the study, subjects were given 0.6-mg (placebo phase) or 0.8-mg (rifampicin phase) buprenorphine sublingually on day 7. In the second part of the study, subjects received 0.4-mg buprenorphine intravenously. Plasma concentrations of buprenorphine and urine concentrations of buprenorphine and its primary metabolite norbuprenorphine were measured over 18 h. Adverse effects were recorded. Rifampicin decreased the mean area under the dose-corrected plasma concentration–time curve (AUC0–18) of sublingual buprenorphine by 25% (geometric mean ratio (GMR): 0.75; 90% confidence interval (CI) of GMR: 0.60, 0.93) and tended to decrease the bioavailability of sublingual buprenorphine, from 22% to 16% (P = 0.31). Plasma concentrations of intravenously administered buprenorphine were not influenced by rifampicin. The amount of norbuprenorphine excreted in the urine was decreased by 65% (P < 0.001) and 52% (P < 0.001) after sublingual and intravenous administration, respectively, by rifampicin. Adverse effects were frequent. Rifampicin decreases the exposure to sublingual but not intravenous buprenorphine. This can be mainly explained by an enhancement of CYP3A-mediated first-pass metabolism, which sublingual buprenorphine only partially bypasses. Concomitant use of rifampicin and low-dose sublingual buprenorphine may compromise the analgesic effect of buprenorphine.Keywords
Funding Information
- Turku University Hospital Research Fund (EVO 13821)
This publication has 45 references indexed in Scilit:
- Buprenorphine Metabolites, Buprenorphine-3-glucuronide and Norbuprenorphine-3-glucuronide, Are Biologically ActiveAnesthesiology, 2011
- Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patientsDrug and Alcohol Dependence, 2011
- Differential Involvement of P-Glycoprotein (ABCB1) in Permeability, Tissue Distribution, and Antinociceptive Activity of Methadone, Buprenorphine, and Diprenorphine: In Vitro and In Vivo EvaluationJournal of Pharmaceutical Sciences, 2009
- Interaction between buprenorphine and atazanavir or atazanavir/ritonavirDrug and Alcohol Dependence, 2007
- Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse historyJournal of Pain and Symptom Management, 2004
- Pharmacokinetics and Subjective Effects of Sublingual Buprenorphine, Alone or in Combination with NaloxoneClinical Pharmacokinetics, 2004
- Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naı̈ve healthy male volunteers under a naltrexone blockDrug and Alcohol Dependence, 2003
- Pharmacokinetic Interactions with RifampicinClinical Pharmacokinetics, 2003
- Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomesLife Sciences, 1997
- Biliary excretion, metabolism and enterohepatic circulation of buprenorphineXenobiotica, 1981